Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
C2.1.D |
By Age: <15 |
2015 |
2,850 |
C2.1.D |
By Age: <15 |
2015 |
900 |
C2.1.D |
By Age: 15+ |
2015 |
8,550 |
C2.1.D |
By Age: 15+ |
2015 |
2,700 |
C2.1.D |
By Age/Sex: <15 Female |
2015 |
1,368 |
C2.1.D |
By Age/Sex: <15 Female |
2015 |
432 |
C2.1.D |
By Age/Sex: <15 Male |
2015 |
4,104 |
C2.1.D |
By Age/Sex: <15 Male |
2015 |
1,296 |
C2.1.D |
By Age/Sex: 15+ Female |
2015 |
1,482 |
C2.1.D |
By Age/Sex: 15+ Female |
2015 |
468 |
C2.1.D |
By Age/Sex: 15+ Male |
2015 |
4,446 |
C2.1.D |
By Age/Sex: 15+ Male |
2015 |
1,404 |
C2.1.D |
By Sex: Female |
2015 |
2,850 |
C2.1.D |
By Sex: Female |
2015 |
900 |
C2.1.D |
By Sex: Male |
2015 |
8,550 |
C2.1.D |
By Sex: Male |
2015 |
2,700 |
C2.1.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
11,400 |
C2.1.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
3,600 |
C2.1.D |
Sum of Age disaggregates |
2015 |
11,400 |
C2.1.D |
Sum of Age disaggregates |
2015 |
3,600 |
C2.1.D |
Sum of Age/Sex disaggregates |
2015 |
11,400 |
C2.1.D |
Sum of Age/Sex disaggregates |
2015 |
3,600 |
C2.1.D |
Sum of Sex disaggregates |
2015 |
11,400 |
C2.1.D |
Sum of Sex disaggregates |
2015 |
3,600 |
C2.1.D_NGI |
By Age: <15 |
2015 |
3,750 |
C2.1.D_NGI |
By Age: 15+ |
2015 |
11,250 |
C2.1.D_NGI |
By Age/Sex: <15 Female |
2015 |
1,800 |
C2.1.D_NGI |
By Age/Sex: <15 Male |
2015 |
5,400 |
C2.1.D_NGI |
By Age/Sex: 15+ Female |
2015 |
1,950 |
C2.1.D_NGI |
By Age/Sex: 15+ Male |
2015 |
5,850 |
C2.1.D_NGI |
By Sex: Female |
2015 |
3,750 |
C2.1.D_NGI |
By Sex: Male |
2015 |
11,250 |
C2.1.D_NGI |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
15,000 |
C2.1.D_NGI |
Sum of Age disaggregates |
2015 |
15,000 |
C2.1.D_NGI |
Sum of Age/Sex disaggregates |
2015 |
15,000 |
C2.1.D_NGI |
Sum of Sex disaggregates |
2015 |
15,000 |
C2.4.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
3,600 |
C2.4.D |
Number of HIV-positive patients who were screened for TB in HIV care or treatment setting |
2015 |
3,600 |
CARE_CURR |
Age/sex: <1 Female |
2015 |
359 |
CARE_CURR |
Age/sex: <1 Male |
2015 |
331 |
CARE_CURR |
Age/sex: 1-4 Female |
2015 |
359 |
CARE_CURR |
Age/sex: 1-4 Male |
2015 |
331 |
CARE_CURR |
Age/sex: 10-14 Female |
2015 |
718 |
CARE_CURR |
Age/sex: 10-14 Male |
2015 |
662 |
CARE_CURR |
Age/sex: 15-19 Female |
2015 |
1,435 |
CARE_CURR |
Age/sex: 15-19 Male |
2015 |
2,245 |
CARE_CURR |
Age/sex: 20-24 Female |
2015 |
1,794 |
CARE_CURR |
Age/sex: 20-24 Male |
2015 |
2,576 |
CARE_CURR |
Age/sex: 25-49 Female |
2015 |
1,794 |
CARE_CURR |
Age/sex: 25-49 Male |
2015 |
1,656 |
CARE_CURR |
Age/sex: 5-9 Female |
2015 |
359 |
CARE_CURR |
Age/sex: 5-9 Male |
2015 |
331 |
CARE_CURR |
Age/sex: 50+ Female |
2015 |
359 |
CARE_CURR |
Age/sex: 50+ Male |
2015 |
331 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
2,714 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
2,576 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
5,382 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
4,968 |
CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
15,640 |
CARE_CURR |
Sum of Age/Sex disaggregates |
2015 |
15,640 |
CARE_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
15,640 |
CARE_NEW |
Age/sex: 1-4 Female |
2015 |
567 |
CARE_NEW |
Age/sex: 1-4 Male |
2015 |
378 |
CARE_NEW |
Age/sex: 10-14 Female |
2015 |
1,215 |
CARE_NEW |
Age/sex: 10-14 Male |
2015 |
810 |
CARE_NEW |
Age/sex: 15-19 Female |
2015 |
1,134 |
CARE_NEW |
Age/sex: 15-19 Male |
2015 |
756 |
CARE_NEW |
Age/sex: 20-24 Female |
2015 |
1,701 |
CARE_NEW |
Age/sex: 20-24 Male |
2015 |
2,134 |
CARE_NEW |
Age/sex: 25-49 Female |
2015 |
1,984 |
CARE_NEW |
Age/sex: 25-49 Male |
2015 |
2,323 |
CARE_NEW |
Age/sex: 5-9 Female |
2015 |
1,215 |
CARE_NEW |
Age/sex: 5-9 Male |
2015 |
810 |
CARE_NEW |
Age/sex: 50+ Female |
2015 |
284 |
CARE_NEW |
Age/sex: 50+ Male |
2015 |
189 |
CARE_NEW |
Aggregated Age/sex: <15 Female |
2015 |
3,997 |
CARE_NEW |
Aggregated Age/sex: <15 Male |
2015 |
1,998 |
CARE_NEW |
Aggregated Age/sex: 15+ Female |
2015 |
5,103 |
CARE_NEW |
Aggregated Age/sex: 15+ Male |
2015 |
4,402 |
CARE_NEW |
Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
15,500 |
CARE_NEW |
Sum of Age/sex disaggregates |
2015 |
15,500 |
CARE_NEW |
Sum of Aggregated Age/sex disaggregates |
2015 |
15,500 |
CARE_SITE |
By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
12 |
CARE_SITE |
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services |
2015 |
17 |
CARE_SITE |
By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
142 |
CARE_SITE |
By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services |
2015 |
194 |
CARE_SITE |
Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
154 |
CARE_SITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
154 |
CARE_SITE |
Total number of PEPFAR supported sites providing clinical care services |
2015 |
211 |
CARE_SITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
211 |
FN_THER |
Age: <1 |
2015 |
250 |
FN_THER |
Age: 1-4 |
2015 |
200 |
FN_THER |
Age: 15-17 |
2015 |
500 |
FN_THER |
Age: 5-14 |
2015 |
250 |
FN_THER |
Aggregated Age: <18 |
2015 |
1,200 |
FN_THER |
Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period |
2015 |
1,200 |
FN_THER |
Number of PLHIV who were nutritionally assessed and found to be clinically undernourished |
2015 |
12,027 |
FN_THER |
Sum of Age disaggregates |
2015 |
1,200 |
FN_THER |
Sum of Aggregated Age disaggregates |
2015 |
1,200 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
5,216 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
5,670 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
454 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
3,478 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
3,780 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
302 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
11,178 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
12,150 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
972 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
7,452 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
8,100 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
648 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
10,433 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
11,340 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
907 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
6,955 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
7,560 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
605 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
15,649 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
17,010 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
1,361 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
10,433 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
11,340 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
907 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
18,257 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
19,845 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
1,588 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
12,172 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
13,230 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
1,058 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
11,178 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
12,150 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
972 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
7,452 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
8,100 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
648 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
2,608 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
2,835 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
227 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
1,739 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
1,890 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
151 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
27,572 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
2,398 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
18,382 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
1,598 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
46,948 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
4,082 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
31,298 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
2,722 |
HTS_TST |
Aggregated Age/sex: <15 Female |
2015 |
29,970 |
HTS_TST |
Aggregated Age/sex: <15 Male |
2015 |
19,980 |
HTS_TST |
Aggregated Age/sex: 15+ Female |
2015 |
51,030 |
HTS_TST |
Aggregated Age/sex: 15+ Male |
2015 |
34,020 |
HTS_TST |
By Test Result: Negative |
2015 |
111,780 |
HTS_TST |
By Test Result: Negative |
2015 |
121,500 |
HTS_TST |
By Test Result: Negative |
2015 |
9,720 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
124,200 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
135,000 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
10,800 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
124,200 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
135,000 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
10,800 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
45,954 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
49,950 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
3,996 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
78,246 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
85,050 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
6,804 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
124,200 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
135,000 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
10,800 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
124,200 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
135,000 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
10,800 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
12,420 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
13,500 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
1,080 |
LAB_ACC |
By site support type: Direct Service Delivery (DSD) |
2015 |
1 |
LAB_ACC |
Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation |
2015 |
1 |
LAB_ACC |
Sum of Support Type disaggregates |
2015 |
1 |
LAB_CAP |
By clinical laboratories |
2015 |
10 |
LAB_CAP |
By site support type: Direct Service Delivery (DSD) |
2015 |
10 |
LAB_CAP |
By site support type: Technical Assistance-only (TA) |
2015 |
10 |
LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2015 |
10 |
LAB_CAP |
Sum of Site Support Type disaggregates |
2015 |
20 |
PMTCT_ARV |
Life-long ART (including Option B+) |
2015 |
2,194 |
PMTCT_ARV |
Life-long ART (including Option B+) |
2015 |
279 |
PMTCT_ARV |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
548 |
PMTCT_ARV |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
93 |
PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
2,194 |
PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
465 |
PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
2,194 |
PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
279 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
1,371 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
175 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
823 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
104 |
PMTCT_ARV |
Sum of New and Current disaggregates |
2015 |
2,194 |
PMTCT_ARV |
Sum of New and Current disaggregates |
2015 |
279 |
PMTCT_ARV |
Sum of Regimen Type disaggregates |
2015 |
2,742 |
PMTCT_ARV |
Sum of Regimen Type disaggregates |
2015 |
372 |
PMTCT_ARV_NGI |
Life-long ART (including Option B+) |
2015 |
3,207 |
PMTCT_ARV_NGI |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
641 |
PMTCT_ARV_NGI |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
3,207 |
PMTCT_ARV_NGI |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
3,207 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
2,005 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
1,202 |
PMTCT_ARV_NGI |
Sum of New and Current disaggregates |
2015 |
3,207 |
PMTCT_ARV_NGI |
Sum of Regimen disaggregates |
2015 |
3,848 |
PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2015 |
2,194 |
PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2015 |
244 |
PMTCT_EID |
By infants with a positive virologic test result within 12 months of birth |
2015 |
122 |
PMTCT_EID |
Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) |
2015 |
3,207 |
PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2015 |
2,438 |
PMTCT_EID |
Sum of Infant Age disaggregates |
2015 |
2,438 |
PMTCT_SITE |
By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women |
2015 |
15 |
PMTCT_SITE |
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) |
2015 |
15 |
PMTCT_SITE |
By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women |
2015 |
88 |
PMTCT_SITE |
By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) |
2015 |
88 |
PMTCT_SITE |
Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women |
2015 |
103 |
PMTCT_SITE |
Sum of Numerator Support Type disaggregates |
2015 |
103 |
PMTCT_SITE |
Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) |
2015 |
103 |
PMTCT_SITE_den |
Sum of Denominator Support Type disaggregates |
2015 |
103 |
PMTCT_STAT |
By: Known positives at entry |
2015 |
686 |
PMTCT_STAT |
By: Known positives at entry |
2015 |
116 |
PMTCT_STAT |
By: Number of new positives identified |
2015 |
2,057 |
PMTCT_STAT |
By: Number of new positives identified |
2015 |
349 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2015 |
24,055 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2015 |
4,080 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
22,853 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
3,876 |
PMTCT_STAT |
Sum of Positives Status disaggregates |
2015 |
2,743 |
PMTCT_STAT |
Sum of Positives Status disaggregates |
2015 |
465 |
PMTCT_STAT_NGI |
By: Known positives at entry |
2015 |
802 |
PMTCT_STAT_NGI |
By: Number of new positives identified |
2015 |
2,406 |
PMTCT_STAT_NGI |
Number of new ANC and L&D clients |
2015 |
28,135 |
PMTCT_STAT_NGI |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
26,728 |
PMTCT_STAT_NGI |
Sum of Positives Status disaggregates |
2015 |
3,208 |
PP_PREV |
Age/sex: 10-14 Female |
2015 |
2,522 |
PP_PREV |
Age/sex: 10-14 Male |
2015 |
2,328 |
PP_PREV |
Age/sex: 15-19 Female |
2015 |
7,566 |
PP_PREV |
Age/sex: 15-19 Male |
2015 |
6,984 |
PP_PREV |
Age/sex: 20-24 Female |
2015 |
15,132 |
PP_PREV |
Age/sex: 20-24 Male |
2015 |
13,968 |
PP_PREV |
Age/sex: 25-49 Female |
2015 |
20,176 |
PP_PREV |
Age/sex: 25-49 Male |
2015 |
18,624 |
PP_PREV |
Age/sex: 50+ Female |
2015 |
5,044 |
PP_PREV |
Age/sex: 50+ Male |
2015 |
4,656 |
PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2015 |
97,000 |
PP_PREV |
Sum of Age/Sex disaggregates |
2015 |
97,000 |
PP_PREV |
Total number of people in the target population |
2015 |
975,282 |
SITE_SUPP |
By program area/support type: Care and Support Technical Assistance-only (TA) |
2015 |
211 |
SITE_SUPP |
By program area/support type: General Population Prevention Technical Assistance-only (TA) |
2015 |
211 |
SITE_SUPP |
By program area/support type: HTC Direct Service Delivery (DSD) |
2015 |
3 |
SITE_SUPP |
By program area/support type: HTC Technical Assistance-only (TA) |
2015 |
208 |
SITE_SUPP |
By program area/support type: Key Populations Prevention Technical Assistance-only (TA) |
2015 |
1 |
SITE_SUPP |
By program area/support type: Lab Direct Service Delivery (DSD) |
2015 |
3 |
SITE_SUPP |
By program area/support type: Lab Technical Assistance-only (TA) |
2015 |
8 |
SITE_SUPP |
By program area/support type: PMTCT Direct Service Delivery (DSD) |
2015 |
12 |
SITE_SUPP |
By program area/support type: PMTCT Technical Assistance-only (TA) |
2015 |
99 |
SITE_SUPP |
By program area/support type: TB/HIV Direct Service Delivery (DSD) |
2015 |
6 |
SITE_SUPP |
By program area/support type: TB/HIV Technical Assistance-only (TA) |
2015 |
185 |
SITE_SUPP |
By program area/support type: Treatment Direct Service Delivery (DSD) |
2015 |
15 |
SITE_SUPP |
By program area/support type: Treatment Technical Assistance-only (TA) |
2015 |
16 |
SITE_SUPP |
By program area/support type: VMMC Direct Service Delivery (DSD) |
2015 |
24 |
SITE_SUPP |
Number of unique sites supported by PEPFAR |
2015 |
211 |
TB_ARTSITE |
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units |
2015 |
31 |
TB_ARTSITE |
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period |
2015 |
31 |
TB_ARTSITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
31 |
TB_ARTSITE |
The number of PEPFAR-supported TB basic management units |
2015 |
31 |
TB_ARTSITE |
The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period |
2015 |
31 |
TB_ARTSITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
31 |
TB_SCREEN |
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period |
2015 |
1,000 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
16 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
2 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
12 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
1 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
55 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
6 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
42 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
5 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
5,174 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
575 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
4,497 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
500 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
518 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
58 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
510 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
57 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
16 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
2 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
12 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
1 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
589 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
66 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
564 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
63 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
5,174 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
575 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
4,497 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
500 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
10,824 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
1,204 |
TX_CURR |
Sum of age/sex disaggregates |
2015 |
129 |
TX_CURR |
Sum of Age/Sex disaggregations |
2015 |
1,153 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
1,153 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
129 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
9,671 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
1,075 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
10,824 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
1,204 |
TX_CURR_NGI |
Age/Sex: <1 Female |
2015 |
18 |
TX_CURR_NGI |
Age/Sex: <1 Male |
2015 |
13 |
TX_CURR_NGI |
Age/Sex: 1-4 Female |
2015 |
61 |
TX_CURR_NGI |
Age/Sex: 1-4 Male |
2015 |
46 |
TX_CURR_NGI |
Age/Sex: 15+ Female |
2015 |
5,749 |
TX_CURR_NGI |
Age/Sex: 15+ Male |
2015 |
4,997 |
TX_CURR_NGI |
Age/Sex: 5-14 Female |
2015 |
576 |
TX_CURR_NGI |
Age/Sex: 5-14 Male |
2015 |
566 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Female |
2015 |
18 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Male |
2015 |
13 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Female |
2015 |
655 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Male |
2015 |
625 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Female |
2015 |
5,749 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Male |
2015 |
4,997 |
TX_CURR_NGI |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
12,026 |
TX_CURR_NGI |
Sum of Age/Sex disaggregates |
2015 |
12,026 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex <15 |
2015 |
1,280 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex 15+ |
2015 |
10,746 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex disaggregates |
2015 |
12,026 |
TX_DIST |
Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District |
2015 |
16 |
TX_DIST |
Total number of PEPFAR supported District Health Offices |
2015 |
16 |
TX_NEW |
Aggregated Grouping by Age: <1 Male |
2015 |
7 |
TX_NEW |
Aggregated Grouping by Age/Sex: <1 Female |
2015 |
7 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2015 |
851 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2015 |
170 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2015 |
1,250 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2015 |
1,282 |
TX_NEW |
By Age/Sex: <1 Female |
2015 |
7 |
TX_NEW |
By Age/Sex: <1 Male |
2015 |
7 |
TX_NEW |
By Age/Sex: 1-4 Female |
2015 |
370 |
TX_NEW |
By Age/Sex: 1-4 Male |
2015 |
34 |
TX_NEW |
By Age/Sex: 10-14 Female |
2015 |
104 |
TX_NEW |
By Age/Sex: 10-14 Male |
2015 |
95 |
TX_NEW |
By Age/Sex: 15-19 Female |
2015 |
385 |
TX_NEW |
By Age/Sex: 15-19 Male |
2015 |
256 |
TX_NEW |
By Age/Sex: 20-24 Female |
2015 |
1 |
TX_NEW |
By Age/Sex: 20-24 Male |
2015 |
449 |
TX_NEW |
By Age/Sex: 25-49 Female |
2015 |
769 |
TX_NEW |
By Age/Sex: 25-49 Male |
2015 |
513 |
TX_NEW |
By Age/Sex: 5-9 Female |
2015 |
370 |
TX_NEW |
By Age/Sex: 5-9 Male |
2015 |
34 |
TX_NEW |
By Age/Sex: 50+ Female |
2015 |
95 |
TX_NEW |
By Age/Sex: 50+ Male |
2015 |
64 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2015 |
3,553 |
TX_NEW |
Pregnancy status |
2015 |
192 |
TX_NEW |
Sum of Age/Sex disaggregates |
2015 |
3,553 |
TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2015 |
3,553 |
TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2015 |
3,307 |
TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2015 |
3,556 |
TX_SITE |
By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation |
2015 |
3,307 |
TX_SITE |
By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites |
2015 |
3,556 |
TX_SITE |
Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation |
2015 |
3,307 |
TX_SITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
3,307 |
TX_SITE |
Total number of PEPFAR-supported ART sites |
2015 |
3,556 |
TX_SITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
3,556 |
VMMC_AE |
Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) |
2015 |
120 |
VMMC_CIRC |
By Age: <1 |
2015 |
200 |
VMMC_CIRC |
By Age: 1-9 |
2015 |
400 |
VMMC_CIRC |
By Age: 10-14 |
2015 |
400 |
VMMC_CIRC |
By Age: 15-19 |
2015 |
800 |
VMMC_CIRC |
By Age: 20-24 |
2015 |
1,000 |
VMMC_CIRC |
By Age: 25-49 |
2015 |
1,000 |
VMMC_CIRC |
By Age: 50+ |
2015 |
200 |
VMMC_CIRC |
By circumcision technique: Surgical VMMC |
2015 |
4,000 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery |
2015 |
80 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2015 |
3,920 |
VMMC_CIRC |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2015 |
4,000 |
VMMC_CIRC |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2015 |
4,000 |
VMMC_CIRC |
Sum of age disaggregates |
2015 |
4,000 |
VMMC_CIRC_NGI |
By Age: <1 |
2015 |
200 |
VMMC_CIRC_NGI |
By Age: 1-9 |
2015 |
400 |
VMMC_CIRC_NGI |
By Age: 10-14 |
2015 |
400 |
VMMC_CIRC_NGI |
By Age: 15-19 |
2015 |
800 |
VMMC_CIRC_NGI |
By Age: 20-24 |
2015 |
1,000 |
VMMC_CIRC_NGI |
By Age: 25-49 |
2015 |
1,000 |
VMMC_CIRC_NGI |
By Age: 50+ |
2015 |
200 |
VMMC_CIRC_NGI |
By circumcision technique: Surgical VMMC |
2015 |
4,000 |
VMMC_CIRC_NGI |
By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery |
2015 |
80 |
VMMC_CIRC_NGI |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2015 |
3,920 |
VMMC_CIRC_NGI |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2015 |
4,000 |
VMMC_CIRC_NGI |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2015 |
4,000 |
VMMC_CIRC_NGI |
Sum of Age disaggregates |
2015 |
4,000 |